197 related articles for article (PubMed ID: 19690388)
1. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium.
Lee D; Yu M; Lee E; Kim H; Yang Y; Kim K; Pannicia C; Kurie JM; Threadgill DW
J Clin Invest; 2009 Sep; 119(9):2702-13. PubMed ID: 19690388
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-specific ERBB3 deletion results in a genetic background-dependent increase in intestinal and colon polyps that is mediated by EGFR.
Mantilla Rojas C; McGill MP; Salvador AC; Bautz D; Threadgill DW
PLoS Genet; 2021 Nov; 17(11):e1009931. PubMed ID: 34843459
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 and ErbB3 regulate recovery from dextran sulfate sodium-induced colitis by promoting mouse colon epithelial cell survival.
Zhang Y; Dubé PE; Washington MK; Yan F; Polk DB
Lab Invest; 2012 Mar; 92(3):437-50. PubMed ID: 22157714
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
[TBL] [Abstract][Full Text] [Related]
5. Kinase activity of ERBB3 contributes to intestinal organoids growth and intestinal tumorigenesis.
Nguyen AT; Lee SY; Chin HJ; Le QV; Lee D
Cancer Sci; 2020 Jan; 111(1):137-147. PubMed ID: 31724799
[TBL] [Abstract][Full Text] [Related]
6. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
Cook RS; Garrett JT; Sánchez V; Stanford JC; Young C; Chakrabarty A; Rinehart C; Zhang Y; Wu Y; Greenberger L; Horak ID; Arteaga CL
Cancer Res; 2011 Jun; 71(11):3941-51. PubMed ID: 21482676
[TBL] [Abstract][Full Text] [Related]
7. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K
Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284
[TBL] [Abstract][Full Text] [Related]
8. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
[TBL] [Abstract][Full Text] [Related]
9. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
10. Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis.
Scheving LA; Zhang X; Stevenson MC; Weintraub MA; Abbasi A; Clarke AM; Threadgill DW; Russell WE
Am J Physiol Gastrointest Liver Physiol; 2015 Dec; 309(12):G942-54. PubMed ID: 26492920
[TBL] [Abstract][Full Text] [Related]
11. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
[TBL] [Abstract][Full Text] [Related]
12. ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.
Frey MR; Hilliard VC; Mullane MT; Polk DB
Lab Invest; 2010 Oct; 90(10):1415-24. PubMed ID: 20585313
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes.
Dahlhoff M; Gaborit N; Bultmann S; Leonhardt H; Yarden Y; Schneider MR
FEBS J; 2017 Oct; 284(19):3339-3349. PubMed ID: 28805349
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
16. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
17. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
19. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
20. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
